Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Burkitt Lymphoma 14Lymphoma, Large B-Cell, Diffuse 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Wilms Tumor 3Sarcoma, Ewing 3Rhabdomyosarcoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 3Lymphoma 3Plasmablastic Lymphoma 2Neoplasms 2Medulloblastoma 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Ganglioneuroblastoma 2Down Syndrome 2Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdoid Tumor 1Osteosarcoma 1Neuroblastoma 1Multi-centric Castleman's Disease 1Malignant mesenchymal tumor 1

Interventions

Cyclophosphamide 9fludarabine 5zanubrutinib 3Vincristine 3Rituximab 3Doxorubicin 3pirtobrutinib 2cemiplimab 2Specimen Handling 2Prednisone 2Magnetic Resonance Spectroscopy 2Leukapheresis 2Immunotherapy, Adoptive 2Etoposide 2Dexamethasone 2Cell- and Tissue-Based Therapy 2tafasitamab 1sodium-iodide symporter 1selinexor 1ruxolitinib 1pomalidomide 1polatuzumab vedotin 1obinutuzumab 1ibrutinib 1glofitamab 1etoposide phosphate 1blinatumomab 1acalabrutinib 1X-Rays 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × Vincristine × 30 days × Clear all
NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Columbia University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

NCT07588698 2026-05-15

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

University of California, San Francisco

Phase 2 Not yet recruiting
20 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡